ALAMEDA, CA, September 23, 2019 — Magnetic Insight, Inc., the leader in Magnetic Particle Imaging (MPI) solutions, announced today that it was awarded a Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health under Award Number R43CA233155. During the twelve-month project, entitled “Development of a commercial Magnetic Particle Imaging platform for the detection and quantification of localized inflammation in cancer,” Magnetic Insight will develop new cancer immunology tools for visualizing inflammation. The project is led by Principal Investigator Patrick Goodwill, Chief Technology Officer of Magnetic Insight. Read more
Magnetic Insight Introduces MOMENTUM CT, the First Commercial MPI with integrated CT
ALAMEDA, Calif., Sept. 3, 2019 /PRNewswire/ — Magnetic Insight, Inc., the leader in magnetic particle imaging (MPI) solutions, introduces the first commercially available MPI system with integrated X-ray computed tomography (CT), offering anatomical context to the newest breakthrough molecular imaging modality. The platform debuts September 3rd, 2019 at the World Molecular Imaging Congress (WMIC) in Montreal, Canada.
The MOMENTUM MPI system can now be installed as a base system or with an integrated CT module. The MPI is currently used to investigate new cell therapy treatments, immunology and cancer in preclinical research models. The technology quantitatively detects magnetic nanoparticles tracers anywhere in the body with exceptional contrast, sensitivity, and resolution to image functional events in the body. While MPI offers high contrast detection of functional events in the body such as cell trafficking to disease sites and inflammation, it does not image anatomical structures. By integrating CT, researchers will have the ability to identify precise locations of these events based on tissue and bone structures. Read More
New Momentum Magnetic Particle Imaging Scanner to be installed in Baltimore, MD
Baltimore, Maryland, August 29: A Magnetic Particle Imaging (MPI) scanner will be installed in The F.M. Kirby Imaging Center at Kennedy Krieger Institute in Baltimore, Maryland.
The principal investigator for the project is Jeff Bulte, Ph.D., Professor of Radiology and Radiological Science and Director of Cellular Imaging in the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. Bulte has pioneered novel MRI and MPI immune and stem cell tracking studies using magnetically labeled cells for therapy in dysmyelination, multiple sclerosis, spinal cord injury, stroke, diabetes, myocardial infarction, and cancer.
ALAMEDA, Calif., July 9, 2019 /PRNewswire/ — Magnetic Insight, suppliers of research and diagnostic imaging solutions, announces the completion of their move into a new facility in Alameda, California, to support corporate growth, manufacturing, and R&D infrastructure. The 22,000 square-foot facility provides increased manufacturing capacity for magnetic particle imaging (MPI) systems while enabling new product development and operations. The facility includes a laboratory, a clean room, a demonstration experience space, a manufacturing floor, and a warehouse to support the increasing demand for MPI products.
ALAMEDA, Calif., March 14, 2019 /PRNewswire/ — Magnetic Insight, Inc., the leader in magnetic particle imaging (MPI) solutions, introduces the first localized MPI hyperthermia technology, HYPER, offering millimeter-scale spatial control of magnetic heating for applications in hyperthermia, drug release, and cell activation.
ALAMEDA, Calif., Dec. 12, 2018 /PRNewswire/ — Magnetic Insight, Inc., a developer and manufacturer of transformational in vivo imaging platforms, announced a Series A financing led by 5AM Ventures. The proceeds will allow the company to expand the commercial and operations teams, scale manufacturing, and develop new application areas for the technology. In conjunction with the financing, David Allison, PhD, Partner at 5AM Ventures, and Joe Victor, CEO of RareCyte Inc, will join the board of directors.
Rats and mice get a lot of bad press, but for Steve Conolly, a professor of bioengineering and of electrical engineering and computer sciences, the furry creatures have been stalwart pioneers in the development of a spectacular new medical research technology called magnetic particle imaging (MPI).
Conolly, working with colleagues, postdocs, and students in his lab, has devised groundbreaking imaging systems that use strong magnetic fields to light up targeted diseases anywhere in the body. MPI is extremely sensitive and quickly generates bright, high-contrast images, in many ways outperforming established methods such as computed tomography (CT), nuclear imaging and magnetic resonance imaging (MRI).
KANSAS CITY, Mo., April 19, 2017 /PRNewswire-USNewswire/ — The Angel Capital Association (ACA), the world’s leading professional association for accredited investors, today named three companies as finalists for the 2017 Luis Villalobos Award for ingenuity, creativity, and innovation among startups. The companies, DesignMedix Inc., Magnetic Insight, and Peloton Technology, were selected based on, among other criteria, competitive differentiation in their respective markets and demonstrated progress toward implementing the product, service, or solution. They were among many companies nominated by ACA’s membership of 13,000 angel investors.
Company initiates commercial execution of groundbreaking technology accelerating cell therapy and vascular research with magnetic particle imaging.
ALAMEDA, California, USA July 18, 2016– Magnetic Insight Inc announced today that the company has secured an oversubscribed seed round of $3M. The equity round is led by Sand Hill Angels with contributions from other prominent angel investors and funds including the Stanford-StartX Fund.
Magnetic Insight was founded to commercialize Magnetic Particle Imaging (MPI), a new imaging modality that directly detects magnetic nanoparticle tracers enabling deep tissue imaging of functional events and disease states. Because the tracer is not normally found in the body, MPI offers exceptional contrast and high sensitivity. Many traditional imaging studies involve the use of radiation or toxic agents. MPI raises the bar in imaging safety and advancement with its non-radioactive and quantitative nanoparticle detection technology. The technology is transforming preclinical research and therapy development with the promise of direct translation to the clinical.